Eurocine Vaccines offentliggör valberedning
Eurocine Vaccines valberedning inför årsstämman 2017 består av Gunnar Bergstedt (ordf.), Michael Wolff Jensen och Pär Thuresson. Valberedningen i Eurocine Vaccines inför årsstämman 2017 harRead…
Delårsrapport juli 2016 – mars 2017
Eurocine Vaccines ansökte om tillstånd att genomföra klinisk prövning. Tillstånd beviljades av Läkemedelsverket och etikprövningsnämnden. Vaccinantigen levererades och Eurocine Vaccines startade en klinisk studie medRead…
Eurocine Vaccines has received notice of allowance for a US patent application
Eurocine Vaccines has received notice of allowance in the US for one of its patent applications. The patent application, involving the company´s nasal influenza vaccineRead…
Eurocine Vaccines has received notice of allowance for a US patent application
Eurocine Vaccines has received notice of allowance in the US for one of its patent applications. The patent application, involving the company´s nasal influenza vaccineRead…
Eurocine Vaccines expects clinical results June/July 2017
Eurocine Vaccines expects results from the ongoing immunological analyses in June/July 2017. The samples presently being analyzed were collected during the clinical study on theRead…
Eurocine Vaccines expects clinical results June/July 2017
Eurocine Vaccines expects results from the ongoing immunological analyses in June/July 2017. The samples presently being analyzed were collected during the clinical study on theRead…
Eurocine Vaccines´ nasal influenza vaccine candidate Immunose™ FLU showed good safety in clinical study
Eurocine Vaccines today announced that Immunose™ FLU, a quadrivalent influenza vaccine candidate showed good safety in a clinical phase I/II study. Immunose™ FLU is a novelRead…
Delårsrapport juli – december 2016
Eurocine Vaccines ansökte om tillstånd att genomföra klinisk prövning. Tillstånd beviljades av Läkemedelsverket och etikprövningsnämnden. Vaccinantigen levererades och Eurocine Vaccines startade en klinisk studie medRead…
Kommuniké från årsstämma i Eurocine Vaccines AB
Eurocine Vaccines AB (publ) har den 14 december hållit årsstämma varvid stämman beslutade i enlighet med styrelsens och valberedningens framlagda förslag. De fullständiga beslutsförslagen framgårRead…
Eurocine Vaccines has completed dosing in phase I/II clinical study with nasal influenza vaccine candidate Immunose™ FLU
Eurocine Vaccines today announced that the last dose has been administered in the ongoing phase I/II clinical study of Immunose™ FLU, a quadrivalent influenza vaccineRead…